Announcements Trials
Browse Landscape

Phase

Phase 2 7Phase 3 4Phase 1 3

Status

Active not recruiting 3Recruiting 1

Sponsor Class

NIH 3NETWORK 1

Study Type

Interventional 4

Sponsor

Cancer Type

Lymphoid 4Other hematologic neoplasm 3

Conditions

Burkitt Lymphoma 4Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Leukemia, Biphenotypic, Acute 1Down Syndrome 1

Interventions

pembrolizumab 133Carboplatin 132Cisplatin 119Paclitaxel 104Gemcitabine 89Specimen Handling 82Magnetic Resonance Spectroscopy 82Docetaxel 73Dexamethasone 60Cyclophosphamide 60Pemetrexed 57durvalumab 55Bevacizumab 55Capecitabine 54Radiotherapy 51Doxorubicin 51Oxaliplatin 50Fluorouracil 48Radiation 47Rituximab 43Leucovorin 43Vincristine 41Lenalidomide 40Etoposide 39atezolizumab 37Nivolumab 37Letrozole 36130-nm albumin-bound paclitaxel 32Bortezomib 31Prednisone 30

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 3 × N,N-dicyclohexyl-isoborneol-10-sulfonamide × 90 days × Clear all
NCT02101853 2026-06-03

Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia

National Cancer Institute (NCI)

Phase 3 Active not recruiting
669 enrolled 14 charts
Lymphoid

Burkitt Lymphoma

NCT02003222 2026-05-28

Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia

National Cancer Institute (NCI)

Phase 3 Active not recruiting
488 enrolled 13 charts 1 FDA
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03914625 2026-05-27

A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia

National Cancer Institute (NCI)

Phase 3 Active not recruiting
6,720 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Down Syndrome, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma

NCT03959085 2026-05-05

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

Children's Oncology Group

Phase 3 Recruiting
5,951 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Biphenotypic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡